Skip to main content

Advertisement

Log in

“Tumor immunology meets oncology (TIMO) XII”, April 28th–30th 2016, Halle/Saale, Germany

  • Meeting Report
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abbreviations

APC:

Antigen-presenting cell(s)

ARG1:

Arginase-1

BC:

Breast carcinoma(s)

CAR:

Chimeric antigen receptor(s)

CRC:

Colorectal carcinoma

CTLA4:

Cytotoxic T lymphocyte-associated protein 4

DC:

Dendritic cell(s)

EGR:

Early growth response

ER:

Estrogen receptor

Exo:

Exosome

FHL:

Familial hemophagocytic lymphohistiocytosis

HDAC:

Histone deacetylase

HGF:

Hepatocyte growth factor;

IDO1:

Indoleamine 2,3-dioxygenase 1

IFN:

Interferon

iNOS:

Inducible nitric oxide synthase

mAb:

Monoclonal antibody

MAPK:

Mitogen-activated protein kinase

MDSC:

Myeloid-derived suppressor cell(s)

MHC:

Major histocompatibility complex

miR:

MicroRNA(s)

MITF:

Microphthalmia-associated transcription factor

NBL:

Neuroblastoma

NCR:

Natural cytotoxicity receptor

NK:

Natural killer

NOS:

Nitric oxide species

PBMC:

Peripheral blood mononuclear cell(s)

PCa:

Pancreatic carcinoma(s)

PD1:

Programmed cell death-1

PD-L1:

Programmed cell death ligand 1

RBP:

RNA-binding protein(s)

RCC:

Renal cell carcinoma(s)

RGS-5:

Regulator of the G protein 5

SOD:

Superoxide dismutase

TAA:

Tumor-associated antigen(s)

TAM:

Tumor-associated macrophage(s)

TAP:

Transporter with antigen processing

TCR:

T cell receptor(s)

TIL:

Tumor infiltrating lymphocyte(s)

TKI:

Tyrosine kinase inhibitor(s)

TLR:

Toll-like receptor(s)

TME:

Tumor microenvironment

TNF:

Tumor necrosis factor

Treg:

Regulatory T cell(s)

VEGF:

Vascular endothelial growth factor

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Barbara Seliger.

Ethics declarations

Conflict of interest

The author declares that she has no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seliger, B. “Tumor immunology meets oncology (TIMO) XII”, April 28th–30th 2016, Halle/Saale, Germany. Cancer Immunol Immunother 66, 1497–1503 (2017). https://doi.org/10.1007/s00262-017-2037-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-017-2037-4

Keywords

Navigation